Strong board and owners to aid search for replacement
Mr. Axelsson instrumental in the success story
Yesterday, Vitrolife announced that its CEO, Thomas Axelsson, has informed the board of his intentions to retire. The board has initiated a process to replace Mr. Axelsson, who will stay on as CEO until a successor has been recruited. Mr. Axelsson has been the CEO since late 2011 and has led the success story that Vitrolife has been on, which has included a share price appreciation of +4000% in addition to the distribution of shares in XVIVO (SEK 6bn market cap). He has also been behind multiple successful acquisitions, including the early expansion into Time-Lapse technology.
The timing of his retirement is logical
While one could have seen Mr Axelsson staying on for longer, we also find the timing logical. Following the acquisition of Igenomix, Vitrolife has entered a new phase focused on building a global organization, integration and extracting synergies.
In a good position to find the right replacement
Considering the strong long-term tailwinds driving Vitrolife’s business, its strong market position and relatively large size, we believe the CEO job should be highly attractive. Furthermore, we believe the process to find the right replacement will be supported by its strong board and owners, which includes among others William Demant Invest, Bure Equity and EQT.
Läs mer på ABG Sundal Collier
Aktuellt
SENASTE
